Axcella Therapeutics

According to the National Institutes for Health, some form of long Covid affects around 10% of people infected with Covid-19, with fatigue being the most common symptom. Despite the size of the market and the global impact, there are currently no effective treatments. Diana Spencer caught up with Bill Hinshaw, President & CEO of Axcella […]

The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125. AXA1125 is a novel composition of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. In April, The Lancet published the results of Axcella’s Phase IIa trial, which showed […]

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. The study found that participants given the treatment, AXA1125, developed by US pharmaceutical company Axcella Therapeutics, felt less fatigued than those given a placebo. Emerging data on long Covid […]